🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥How is early relapsed multiple myeloma treated today? Check out this new video with Dr. Joseph Mikhael as he reveals the latest strategies, including CAR-T therapies & XPO1 inhibitors, and how to manage side effects effectively. 🎞️ ow.ly/9cG850ToIhA #MedEd

🔥#ESMO2024 I 802MO 📊Teclistamab vs. BCMA CAR-T in #MM: CAR-T had better 2-year OS vs. teclistamab. CRS incidence higher with CAR-T (54% vs. 18%), while ICANS was similar (9% both). Older pts (≥70) saw significant benefits (OS HR 0.197). ow.ly/6M6M50TwBfR #MedEd

🔥#ESMO2024 I 801MO Timdarpacept + AZA in Newly Diagnosed CMML 📊🔹 ORR: 72.7% (CR 27.3%) 🔹CR Rate: 46.2% for ≥6 mos treatment 🔹 Median TTR: 1.8 months🔹 Median DoR: 14.1 mos 🔹 12-month OS: 66.7%. AEs: lymphopenia, leukopenia, neutropenia. ow.ly/OHXC50TwBaE #MedEd

📊 In a study of 302 pts, isatuximab showed median OS NR vs. 50.60 mos for control. At 48 mos, survival was 59.7% vs. 52.2%. HR for time to next tx: 0.583 (p=0.0002). Common AEs: infusion rxns (46% vs. 3%),URTIs (40% vs. 28%). In The Lancet Haematology: ow.ly/SMP450TwBCe #MedEd

Do you know how early relapsed #multiplemyeloma is treated today? Dr Joseph Mikhael reveals the latest strategies, including CAR-T therapies & XPO1 inhibitors, and how to manage side effects effectively in this short video 📺 Slides also available for download

⚡Phase 1 trial (NCT04822337) shows Belantamab mafodotin-blmf (Blenrep) + KRd yields deep responses in relapsed multiple myeloma with manageable safety. Max tolerated dose: 1.9 mg/kg every 8 weeks; 24-month PFS: 80%. Further studies planned. ow.ly/bkMQ50TFajV #MedEd

Did you catch our recent video with Dr Elena Zamagni? Listen as she discusses the current treatment landscape and challenges in #RRMM and the need for new therapies 📺 Slides also available cor2ed.com/lymphoma-myelo… #MedEd #MMSM

🚨 AURIGAPhase 3 trial: Daratumumab + lenalidomide doubled MRD-negative rates vs lenalidomide alone in newly diagnosed multiple myeloma post-transplant. 💡 12-month MRD-neg rates: 👉 Combo: 50.5% 👉 Lenalidomide: 18.8% Manageable Safety. ow.ly/ys5B50TKmpT #MedEd #MM

🦵 Persistent leg pain in #MultipleMyeloma could signal bone involvement, nerve compression, or vascular issues. #MedEd x.com/MyMyelomaTeam/…

What’s the future of bispecific antibodies in relapsed #MM❓ A new review explores high response rates, lower CRS/neurotox vs CAR-T, infection risks, and resistance from chronic therapy. Plus, promising new T-cell engagers are on the horizon! 👉ow.ly/CEnH50TKmzx #MedEd

What are the most pressing unmet needs in treating early relapses of #MM? How have recent advancements impacted patient outcomes, and what do the guidelines say? Our latest video addresses these key questions in treatment and patient care! ow.ly/97Z350TKwfI #MedEd

Did you catch the recent video 📺 of Dr Fredrik Schjesvold as he discusses the need for new MoAs in #RRMM? Key points:🔹Disease heterogeneity🔹Switching drug classes🔹Novel MoAs for refractory cases👇 cor2ed.com/lymphoma-myelo… Watch the video and download the slides #MMSM

So good to see COR2ED reach 3000 subscribers on YouTube! 👏 #MedEd

Do you know how early relapsed #multiplemyeloma is treated today? In this short video, Dr Joseph Mikhael reveals the latest strategies, including CAR-T therapies & XPO1 inhibitors, and how to manage side effects effectively 📺 Slides also available for download

We are heading to #EHA2025 in Milan tomorrow! We’re looking forward to hearing the latest advances in hematology and exploring how they can support healthcare professionals and patients around the world. If you’re attending, we’d be delighted to meet — feel free to reach out!

Do you follow COR2ED on YouTube? Now at over 12k subscribers! 🎉 #HemOnc #Oncology #MedEd